- Home
- ODYS vs CNTX Comparison
ODYS vs CNTX Comparison
Compare ODYS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- CNTX
- Stock Information
- Founded
- ODYS N/A
- CNTX 2015
- Country
- ODYS Israel
- CNTX United States
- Employees
- ODYS N/A
- CNTX N/A
- Industry
- ODYS
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ODYS
- CNTX Health Care
- Exchange
- ODYS NYSE
- CNTX Nasdaq
- Market Cap
- ODYS 86.1M
- CNTX 78.0M
- IPO Year
- ODYS N/A
- CNTX 2021
- Fundamental
- Price
- ODYS $5.00
- CNTX $0.64
- Analyst Decision
- ODYS Strong Buy
- CNTX Strong Buy
- Analyst Count
- ODYS 1
- CNTX 5
- Target Price
- ODYS $10.00
- CNTX $5.50
- AVG Volume (30 Days)
- ODYS 12.0K
- CNTX 313.4K
- Earning Date
- ODYS 08-11-2025
- CNTX 08-06-2025
- Dividend Yield
- ODYS N/A
- CNTX N/A
- EPS Growth
- ODYS N/A
- CNTX N/A
- EPS
- ODYS N/A
- CNTX N/A
- Revenue
- ODYS $5,842,000.00
- CNTX N/A
- Revenue This Year
- ODYS N/A
- CNTX N/A
- Revenue Next Year
- ODYS N/A
- CNTX N/A
- P/E Ratio
- ODYS N/A
- CNTX N/A
- Revenue Growth
- ODYS 100.27
- CNTX N/A
- 52 Week Low
- ODYS $4.00
- CNTX $0.49
- 52 Week High
- ODYS $10.80
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- CNTX 49.49
- Support Level
- ODYS N/A
- CNTX $0.62
- Resistance Level
- ODYS N/A
- CNTX $0.70
- Average True Range (ATR)
- ODYS 0.00
- CNTX 0.05
- MACD
- ODYS 0.00
- CNTX 0.01
- Stochastic Oscillator
- ODYS 0.00
- CNTX 57.14
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.